NCT03000257: A Study of ABBV-181 in Participants With Advanced Solid Tumors

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 99 Years (Adult, Senior)
Location of Metastases: 
Additional Notes: Participant must be PD-I/PD-L1 targeting agent naïve for the expansion phase
Exclusions: Known uncontrolled metastases to the central nervous system (CNS)- see trial for details

Comments are closed.

Up ↑